STAT3 Inhibition for Gastroenteropancreatic Neuroendocrine Tumors: Potential for a New Therapeutic Target?

Alexandra G Lopez-AguiarLauren M PostlewaitCecilia G EthunMohammad Y ZaidiKristen ZhelninAlyssa KrasinskasMaria C RussellDavid A KoobyKenneth CardonaBassel F El-RayesShishir K Maithel

Published in: Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract (2019)

In resected GEP-NETs, high STAT3 expression is associated with an increased Ki-67 index, presence of lymphovascular invasion and worse 3-yr RFS. STAT3 may be a novel therapeutic target for patients undergoing resection of high-risk tumors.

Keyphrases

neuroendocrine tumors
patients undergoing
cell proliferation
poor prognosis
lymph node
cell migration
squamous cell carcinoma
risk assessment